Title |
Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma
|
---|---|
Published in |
Journal of Experimental & Clinical Cancer Research, March 2016
|
DOI | 10.1186/s13046-016-0327-x |
Pubmed ID | |
Authors |
Zhen Jin, Kai Qing, Yuan Ouyang, Zhao Liu, Wenfang Wang, Xiaoyang Li, Zizhen Xu, Junmin Li |
Abstract |
Activated B cell-like subtype of diffuse large B cell lymphoma (ABC-DLBCL) presents aggressive clinical courses and poor prognosis. Targeting key pathways may raise the possibility of improving clinical outcomes. The synergetic effects were assessed by CCK-8 assay and measured by isobologram analysis. The NVP-Bez235 and lenalidomide cytotoxicity were measured by flow cytometry, Western Blot and si-RNA transfection. The combined treatment inducing tumor regression in vivo was performed in nude mice of OCI-Ly10 xenograft mouse model. Low dose of two agents represented significant inhibition of proliferation with CI value < 1. NVP-Bez235 combined with lenalidomide remarkably increased apoptosis through intrinsic pathway by upregulating Bim, Bax and downregulating Bcl-xL. Akt, especially NF-κB, played an important role in the synergetic effects. Cotreatment also induced the cell cycle to be arrested in G0/G1 phase, and decreased S phase by increasing p21 expression, downregulating cyclinA and diminishing CDK2 phosphorylation in Su-DHL2 and OCI-Ly3 but not in OCI-Ly10. Mice treated with NVP-Bez235/lenalidomide represented obvious tumor growth regression and prolonged overall survival. Our findings demonstrated the synergistic effect of low dose of NVP-Bez235 and lenalidomide in ABC-DLBCL, the underlying mechanism may be multifunctional, involving apoptosis, Akt and NF-κB inactivation and cell cycle arrest. Cotreatment was also effective in vivo. These data pave the way for potential treatment of ABC-DLBCL with combination of NVP-Bez235 and lenalidomide. |
Twitter Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 3 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 67% |
Scientists | 1 | 33% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 20 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 5 | 25% |
Student > Bachelor | 4 | 20% |
Student > Doctoral Student | 3 | 15% |
Professor > Associate Professor | 2 | 10% |
Student > Master | 2 | 10% |
Other | 4 | 20% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 7 | 35% |
Biochemistry, Genetics and Molecular Biology | 6 | 30% |
Agricultural and Biological Sciences | 2 | 10% |
Engineering | 2 | 10% |
Immunology and Microbiology | 1 | 5% |
Other | 0 | 0% |
Unknown | 2 | 10% |